Medable Introduces Agentic Accelerator Program

Medable Inc. has announced its Agentic Accelerator Program to help life sciences companies transform clinical development with agentic artificial intelligence (AI). The program includes onboarding, integration support, governance, and change management to help sponsors and contract research organizations (CROs) gain value from AI agents.

Twenty-two percent of life sciences leaders have scaled AI across the enterprise, and far fewer have transformed clinical development, according to industry research. As AI capabilities continue to evolve rapidly, companies need hands-on partners who provide both strategic guidance and a path to immediate impact and return on investment (ROI).

Medable’s Agentic Accelerator Program improves time to value by providing strategic guidance and a clear path to implementation and scale. The program supports customers with a team of AI clinical development experts and forward-deployed engineers (FDEs), ensuring that customers can move quickly on standard agentic use cases while also developing proprietary workflows and agentic solutions on the Medable platform.

“Agentic AI is the productivity leverage that bends the time/cost curve of today’s clinical trials. Customers want rapid time to value while also ensuring protection of their proprietary agentic clinical development strategy,” Medable Co-Founder/CEO Michelle Longmire said. “To achieve this, customers need a partner with industry expertise, a fit-for-purpose agentic platform, and a willingness to put skin in the game on the outcomes. Companies that want results choose Medable because it’s the fastest path to scalable agentic transformation for clinical trials.”

Medable is agentifying the clinical development lifecycle, from protocol initiation to study close-out, with Medable Agent Studio, a purpose-built agentic AI platform for clinical development that enables sponsors and CROs to deploy AI agents across clinical workflows. It combines no-code agent creation, human-in-the-loop oversight, GxP-ready compliance controls, a clinical data ontology layer, built-in AI governance, and MCP (Model Context Protocol) connectors across clinical and enterprise systems to automate operational work while maintaining transparency, auditability, and regulatory alignment.

Medable aims to provide effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Leader in eCOA by Everest Group, Medable’s platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than 1 million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, Calif.